¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2020 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2020-02-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2020 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2020-02-01
±³À°ÀÏÀÚ : 2020-02-01
±³À°Àå¼Ò : ¼­¿ï´ëÇб³ Ä¡°úº´¿ø 8Ãþ ´ë°­°­  
±³À°ÁÖÁ¦ : 2020 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581  
À̸ÞÀÏ : bmt@kams.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 10:00~10:40 Cancer Immunotherapy; past, present and future  ¹è¿ë¼ö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 10:40~11:10 Biomedical applications of stimuli responsive nanoparticles  ¹ÚÀαÔ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 11:10~11:40 Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy  À̽¿ì(Æ÷Ç×°ø´ë) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 11:40~12:10 NK cells in cancer immunosurveillance and prognosis  ±èÇå½Ä(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 13:20~14:00 Real world experience of CAR T-cell therapy  Peihua Lu(Hebei Yanda Lu Daopei Hospital, China) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 14:00~14:30 Novel immunotherapeutic approach with antibody drugs  Á¤ÀçÈ£(ABL Bio) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 14:30~15:00 Current status of bispecific T-cell engager for B cell ALL  À±ÀçÈ£(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 15:10~15:50 Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes  Jooeun Bae(Harvard Medical School, USA) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 15:50~16:20 Adoptive T cell immunotherapy – experiences in preclinical and clinical studies  ÃÖ¹ü±Ô(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 02-01 8Ãþ ´ë°­´ç 16:20~16:50 Overcoming refractoriness to immune checkpoint inhibition in multiple myeloma: an ex vivo evidence of combination approach  ÃÖÀ±¼®(Ãæ³²ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2020 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2020-02-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2020³âµµ ÀÓ»ó³úÆÄ µ¿°è ¿öÅ©¼ó : 2020-02-01
´ÙÀ½±Û °Ç±¹´ëÇб³º´¿ø ´ëÇÑ°íÇ÷¾ÐÇÐȸ °íÇ÷¾ÐÇÕº´Áõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2020-02-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20790 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦52Â÷ ÀÎõºÎõÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-15 0 15 2024-05-27
20789 ¼­¿ï 2024³â ´ëÇѽŰæ±ÙÀ°ÁúȯÇÐȸ ¿¬¼ö°­Á : 2024-06-15 0 10 2024-05-27
20788 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-15 0 10 2024-05-27
20787 Ãæ³² (¿Â¶óÀÎ)2024³âµµ Ãæû³²µµÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 12 2024-05-27
20786 ºÎ»ê KSMO ºÎ»ê¿ï»ê°æ³²/´ë±¸°æºÏÁöȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2024-06-14 0 10 2024-05-27
20785 ¼­¿ï 2024³â ´ëÇѺҾÈÀÇÇÐȸ Ãá°èÇмú´ëȸ (´Ù½Ã, °Ü¿ï³ª¹«¿¡¼­ º½ ³ª¹«¿¡·Î From Traditional approaches to Innovation in Psychiatry) : 2024-06-14 0 11 2024-05-27
20784 ¼­¿ï ´ëÇÑ°áÇÙÇùȸ 2024³â °áÇÙ°ü¸®±³À° 1±â(2ÀÏÂ÷) : 2024-06-14 0 7 2024-05-27
20783 ¼­¿ï Á¦14Â÷ Çѱ¹ÃÖ¼Òħ½ÀÃéÀå¼ö¼ú¿¬±¸È¸ : 2024-06-14 0 9 2024-05-27
20782 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç (2ÀÏÂ÷) : 2024-06-14 0 17 2024-05-27
20781 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø RARE DISEASE SYMPOSIUM 2024 : 2024-06-14 0 6 2024-05-27
20780 ºÎ»ê 2024 ´ëÇѽŰæ¿Ü°úÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Á¦2Â÷ Á¤±âÇмú´ëȸ : 2024-06-14 0 14 2024-05-27
20779 ¼­¿ï 2024 ´ëÇÑÀÇÇÐȸ Çмú´ëȸ : 2024-06-14 0 9 2024-05-27
20778 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-14 0 15 2024-05-27
20777 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-14 0 8 2024-05-27
20776 ºÎ»ê 2024³â Çѱ¹°£´ãÃé¿Ü°úÇÐȸ ºÎ¿ï°æÁöȸ °£ÀÌ½Ä ½ÉÆ÷Áö¾ö : 2024-06-14 0 8 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷